about
Overutilization of proton-pump inhibitors: what the clinician needs to knowAcid suppression and the risk of Clostridium difficile infectionAcid suppressive drugs and gastric cancer: a meta-analysis of observational studiesDipyridamole bioavailability in subjects with reduced gastric acidityThe inaccuracy of ICD-9-CM Code 530.2 for identifying patients with Barrett's esophagusDeprescribing proton pump inhibitors: Evidence-based clinical practice guideline.The association between cognition and histamine-2 receptor antagonists in African Americans.Use of acid-suppressive drugs and risk of fracture: a meta-analysis of observational studies.Proton pump inhibitor discontinuation in long-term care.Risk of community-acquired pneumonia with outpatient proton-pump inhibitor therapy: a systematic review and meta-analysis.The impact of proton pump inhibitors on the human gastrointestinal microbiomeH2 receptor antagonists and right ventricular morphology: the MESA right ventricle studyEffects of omeprazole on the pharmacokinetic profiles of lisdexamfetamine dimesylate and extended-release mixed amphetamine salts in adults.Clostridium difficile infection in the community: are proton pump inhibitors to blame?Do proton pump inhibitors decrease calcium absorption?Use of Acid Suppression Medication is Associated With Risk for C. difficile Infection in Infants and Children: A Population-based StudyUse of proton pump inhibitors is associated with fractures in young adults: a population-based study.Systematic review: the efficacy of intermittent and on-demand therapy with histamine H2-receptor antagonists or proton pump inhibitors for gastro-oesophageal reflux disease patients.Review article: the long-term use of proton-pump inhibitors.Use of Proton Pump Inhibitors and the Risk of Hospitalization for Infectious GastroenteritisUse of proton pump inhibitors and risk of osteoporosis-related fractures.Histamine H2 Receptor Antagonists, Left Ventricular Morphology, and Heart Failure Risk: The MESA Study.Effects of rabeprazole on bone metabolic disorders in a gastrectomized rat modelLong-term management of GERD in the elderly with pantoprazole.Use of proton-pump inhibitors among adults: a Danish nationwide drug utilization study.Proton pump inhibitors and risk for recurrent Clostridium difficile infection among inpatients.Proton pump inhibitors: are they overutilised in clinical practice and do they pose significant risk?Effect of long-term proton pump inhibitor administration on gastric mucosal atrophy: A meta-analysis.Acid-Suppressive Therapy and Risk of Infections: Pros and Cons.Re-evaluating the Inhibition of Stress Erosions (REVISE): a protocol for pilot randomized controlled trial.Effect of an antimicrobial stewardship bundle for patients with Clostridium difficile infection.Acid-Suppressing Agents and Risk for Clostridium difficile Infection in Pediatric Patients.Proton pump inhibitors therapy and risk of Clostridium difficile infection: Systematic review and meta-analysis.The distressing overuse of gastric acid inhibitors.Controlled trial of interventions to increase testing and treatment for Helicobacter pylori and reduce medication use in patients with chronic acid-related symptoms.Déprescrire les inhibiteurs de la pompe à protons: Lignes directrices de pratique clinique fondées sur les données probantes.Barrett's esophagus in females: a comparative analysis of risk factors in females and males.No Significant Association Between Proton Pump Inhibitor Use and Risk of Stroke After Adjustment for Lifestyle Factors and Indication.We have had a gutful: The need for deprescribing proton pump inhibitors.Social and medical impact, sleep quality and the pharmaceutical costs of heartburn in Taiwan.
P2860
Q24634086-98E2921C-B48B-4BA0-B03E-DF2DD63B323DQ26823599-04131862-7CF4-4920-8D66-9FC4B0221FFCQ27025101-6C2C0842-1D63-4BB1-9F52-A93F242A99F1Q28177095-5BE513D9-F982-4D81-8068-1B9C7874E1E9Q33397810-7A7FB79B-2C25-4EF8-A564-1002B34902F9Q33675495-A2B18B2A-8015-47C0-8E4B-9BAB3FB07A7CQ33814382-AFD8F4C7-86D0-4D29-B5DD-DE40F5CB6B73Q33893627-C1268A5D-0E8E-4FCC-B080-81627B27C417Q34007345-14D07C03-53A1-4665-B1DF-FE936062C3ABQ34479280-CBDEE063-1CAE-4C6E-98EE-FDCB02BEB95DQ34625008-073A8A76-192B-49D0-B321-52D4D1A1F562Q34984706-B671E0DE-0639-46B2-B89F-B1545C1C5787Q35007442-C9B4F071-656D-413A-A202-BBDC038C7E20Q35031254-56B040D3-D962-4C93-B14E-F742909D2DC0Q35229828-0E749800-1253-42BE-A81C-E75C43139268Q35999704-2897331B-51AA-42E3-B605-660B1FD5B572Q36075131-78B91747-7D2A-41AF-AF7F-97D4678BC556Q36149059-C69D4B6F-4896-4611-BBC0-3053D88B1714Q36206584-4268B86F-BE2B-496A-AA90-0567E30BB798Q36229626-13E09CFC-44A8-4E2B-853E-AFD801C1396CQ36803505-E77B2E05-74F7-4DA8-B816-8B462C34F675Q36881933-D61F2562-922C-4A9A-9D40-720A37A5360DQ37001665-F740E366-B0C6-4D60-80E1-7691575C2A63Q37017283-0627834A-4B2A-4822-A87B-2245C80E0D36Q37173748-0A106DD0-2F4F-4E96-AA4D-E9C6DE636BD6Q37663683-B4667132-94CF-4A1E-8226-E80DA693D9A7Q38011261-9582A9AC-86E3-4B5B-A1C0-DB45DFF9C086Q38672656-3E970D09-D5D7-4D00-968F-C3237BE683D3Q38865456-C6791B54-74D6-4984-8E24-CCA97D8EB063Q39128295-61748767-02FB-42D0-BFE4-243A2169B437Q40873678-48B22875-4825-4B9A-BC43-634B5476F86BQ41508412-3FA78A66-53FF-4625-8B08-6D1CF74E5D1DQ42695192-8E7FC324-2A64-412A-8958-BB67D314F44FQ43526669-555B46A6-2E5C-410B-87D2-EF492BD4B6AEQ44642449-55528C38-9AE7-46B3-BC62-1682E781339AQ46189430-4963DC50-3483-44BF-A1E3-093F502E0523Q46620511-79254F6B-08A6-47B0-A618-C8243BB3C1D4Q47264184-D9AAC2AE-691C-46C7-87F7-C6219099BEEEQ47998734-9F4ECA78-4A94-4573-A559-C5375AA3E72DQ48531759-80C83E65-BB3E-4817-9858-840CA5529B9A
P2860
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Who is using chronic acid suppression therapy and why?
@en
Who is using chronic acid suppression therapy and why?
@nl
type
label
Who is using chronic acid suppression therapy and why?
@en
Who is using chronic acid suppression therapy and why?
@nl
prefLabel
Who is using chronic acid suppression therapy and why?
@en
Who is using chronic acid suppression therapy and why?
@nl
P2093
P2860
P1476
Who is using chronic acid suppression therapy and why?
@en
P2093
Emmanuel M Mahlis
Tara L Shea
Thomas H Lee
Timothy C Wang
Timothy G Ferris
P2860
P356
10.1111/J.1572-0241.2003.07186.X
P407
P577
2003-01-01T00:00:00Z